Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Primary Hormonal Therapy for Ductal Carcinoma in Situ
NCT00290745Phase 2Completed
- Sponsor
- University of California, San Francisco
- Start
- Feb 2002
- Primary completion
- Jul 2009
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tamoxifen and letrozole in ductal carcinoma in situ (DCIS), sponsored by University of California, San Francisco. Primary endpoints: Median Change in 6-month Tumor Volume Compared to Baseline Using Mammography and Median Change in 6-month Tumor Volume Compared to Baseline Using Magnetic Resonance Imaging (MRI). Started Feb 2002; status: completed.
02
Drugs
tamoxifenletrozole
03
Conditions
ductal carcinoma in situ (DCIS)
Beyond the preview
Go deeper on NCT00290745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00290745.